Loading... Please wait...
App Store Download on the App Store Google Play GET IT ON Google Play

MiNK Therapeutics, Inc. (INKT) Stock Price, News & Analysis

Currency in USD Disclaimer
Add to Alerts
Add to Watchlist
$0.92 -$0 (0%)
$0.89
$0.93
$0.75
$2.15
Track all markets on TradingView

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -1,736.38
  • Piotroski Score 1.00
  • Grade Buy

Company brief: MiNK Therapeutics, Inc. (INKT)

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Price Target and Rating

  • $0.00
  • $0.00
  • $0.00
  • N/A
  • Neutral
  • N/A
  • N/A

Profitability

  • -$0.59
  • -1.63
  • -1.63
  • -1.63
  • $-22,457,859

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Latest News of INKT

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Log In

or
Continue with Google Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Sign Up With Email Address
or
Continue with Google Continue with Apple

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.